Get the tools used by (smart)2 investors.

Common Equity

Join now and get access to the full platform

Search for company or ETF

 

  0 results available. Select is focused ,type to refine list, press Down to open the menu,

-
Price
Fair Value
Upside
- - -
52-week range

Analysis

Fiscal Years
Trailing Twelve Months
Fiscal Halfs
Fiscal Quarters
Daily
Hide this widget

The following section summarizes insights on 's Common Equity:

Dec 2016Dec 2018Dec 2020Dec 2022Dec 20240 K50 M100 M150 M

Performance Summary
  • Inozyme Pharma Inc's common equity last quarter was 57.826 million
  • Inozyme Pharma Inc's common equity for fiscal years ending December 2020 to 2024 averaged 116.8 million.
  • Inozyme Pharma Inc's operated at median common equity of 118.4 million from fiscal years ending December 2020 to 2024.
  • Looking back at the last 5 years, Inozyme Pharma Inc's common equity peaked in December 2020 at 158.1 million.
  • Inozyme Pharma Inc's common equity hit its 5-year low in December 2024 of 57.826 million.
  • Inozyme Pharma Inc's common equity decreased in 2021 (109.3 million, -30.9%) and 2024 (57.826 million, -58.8%) and increased in 2020 (158.1 million, -575.9%), 2022 (118.4 million, +8.4%), and 2023 (140.5 million, +18.7%).

How does Inozyme's Common Equity benchmark against competitors?

Hide this widget

Metric Usage: Common Equity

Hide this widget
equity_common
Slug
number
Datatype
text
Format
current
Default Period
FY, Q
Periods Supported
Free
Plan

To view the full list of supported financial metrics please see Complete Metrics Listing.

Similar Metrics

Hide this widget

Metrics similar to Common Equity in the financials category include:

  • Net Change in Cash - The total change in cash for the company over the given period.
  • Minority Interest, Total - The book value of the reporting company's share of ownership in another company.
  • Current Taxes - This item represents the current amount of income taxes payable, both domestic and foreign.
  • Finance Division Debt, Long-Term - This item represents those amounts pertaining to the finance division of an Industrial template company, which are to be repaid in full, usually with interest, that are not currently payable within one year or within the operating cycle of the business.
View Full List

Search for metric or datapoint

Common Equity

The sum of all common equity items

Definition of Common Equity

Hide this widget

Inozyme Pharma reported common equity of 57.826 M for the latest quarter ending December 31, 2024 on its balance sheet.

The tables below summarizes Inozyme Pharma’s Common Equity and common size over the last five years:

Fiscal YearCommon EquityAssets% Assets
2020-12-31158.1 M169.4 M93.4%
2021-12-31109.3 M123.5 M88.4%
2022-12-31118.4 M139.2 M85.1%
2023-12-31140.5 M200.8 M69.9%
2024-12-3157.826 M123.2 M46.9%

The tables below summarizes Inozyme Pharma’s Common Equity and common size over the last four quarters:

Quarter EndingCommon EquityAssets% Assets
2024-03-31118.8 M176.9 M67.2%
2024-06-3094.42 M155.7 M60.6%
2024-09-3082.788 M143.4 M57.7%
2024-12-3157.826 M123.2 M46.9%

Click the link below to download a spreadsheet with an example Common Equity calculation for Inozyme Pharma Inc below:

Sector Benchmark Analysis

Sector
Industry Group
Industry
Hide this widget
0 K3 B6 B11.051 B2006001,0001,400

The chart above depicts the distribution of common equity for companies operating in the Healthcare sector in the Developed economic region. Over 2,490 companies were considered in this analysis, and 2,393 had meaningful values. The average common equity of companies in the sector is 371.9 M with a standard deviation of 1.147 B.

Inozyme Pharma Inc's Common Equity of 57.826 M ranks in the 61.0% percentile for the sector. The following table provides additional summary stats:

Common Equity In The Healthcare Sector
Economic Risk RegionDeveloped
Total Constituents2,493
Included Constituents2,393
Min-97.283 M
Max10.901 B
Median21.705 M
Mean371.9 M
Standard Deviation1.147 B

You can find companies with similar common equity using this stock screener.

All rights reserved. Terms Of Use